陆泓雨,陈纪元,贺子熠,韩江莉

• 1:北京大学第三医院心内科

摘要(Abstract)：

冠心病（CHD）合并慢性肾病（CKD）仍然是一项严峻的临床挑战。CHD的侵入性治疗对于晚期CKD患者具有更高的风险，对比剂肾病的发生已经成为患者生存率降低的独立危险因素。由于大多数临床研究将这类高危人群排除在外，目前很难规范晚期CKD患者的介入策略并平衡不同策略间的可能获益。本文通过系统回顾现有相关临床研究，重点阐述CHD合并CKD患者面临的高临床风险和利用血管内超声指导经皮冠状动脉介入治疗相对于传统介入治疗的优势，以期为这类患者的临床决策提供参考。

关键词(KeyWords)： 冠心病;慢性肾病;经皮冠状动脉介入治疗;血管内超声

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 陆泓雨,陈纪元,贺子熠,韩江莉

参考文献(References)：

• [1] Choi HY, Park HC, Ha SK. How do we manage coronary artery disease in patients with CKD and ESRD[J]? Electrolyte Blood Press, 2014, 12(2):41-54.
• [2] Chen TK, Knicely DH, Grams ME. Chronic kidney disease diagnosis and management:a review[J]. JAMA, 2019,322(13):1294-1304.
• [3] Yang C, Gao B, Zhao X, et al. Executive summary for china kidney disease network(CK-NET)2016 annual data report[J].Kidney Int, 2020, 98(6):1419-1423.
• [4] Lee WC, Wu PJ, Fang CY, et al. Impact of chronic kidney disease on chronic total occlusion revascularization outcomes:a meta-analysis[J]. J Clin Med, 2021, 10(3):440.
• [5] O’gara PT. PCI or CABG for LMCA revascularization in patients with CKD:the jury is still out[J]. J Am Coll Cardiol,2018, 72(7):766-768.
• [6] Silva RP, Diogenes C. Heart disease and the kidneys[J].Contrib Nephrol, 2021, 199:71-79.
• [7] Ishigami J, Trevisan M, Lund LH, et al. Acceleration of kidney function decline after incident hospitalization with cardiovascular disease:the Stockholm CREAtinine Measurements(SCREAM)project[J]. Eur J Heart Fail,2020, 22(10):1790-1799.
• [8] Thompson S, James M, Wiebe N, et al. Cause of death in patients with reduced kidney function[J]. J Am Soc Nephrol,2015, 26(10):2504-2511.
• [9] Huo Y, Van De Werf F, Han Y, et al. Long-term antithrombotic therapy and clinical outcomes in patients with acute coronary syndrome and renal impairment:insights from EPICOR and EPICOR Asia[J]. Am J Cardiovasc Drugs,2021, 21(4):471-482.
• [10] Sarnak MJ, Amann K, Bangalore S, et al. Chronic kidney disease and coronary artery disease:JACC state-of-the-art review[J]. J Am Coll Cardiol, 2019, 74(14):1823-1838.
• [11] Osten MD, Ivanov J, Eichhofer J, et al. Impact of renal insufficiency on angiographic, procedural, and in-hospital outcomes following percutaneous coronary intervention[J].Am J Cardiol, 2008, 101(6):780-785.
• [12] Costanzo P, Dzavik V. Coronary revascularization in patients with advanced chronic kidney disease[J]. Can J Cardiol,2019, 35(8):1002-1014.
• [13] Natale P, Palmer SC, Saglimbene VM, et al. Antiplatelet agents for chronic kidney disease[J]. Cochrane Database Syst Rev, 2022, 2:CD00883 4.
• [14] Latif F, Kleiman NS, Cohen DJ, et al. In-hospital and 1-year out comes among percutane ous coronary intervention patients with chronic kidney disease in the era of drug-eluting stents:a report from the EVENT(evaluation of drug eluting stents and ischemic events)registry[J]. JACC Cardiovasc Interv, 2009, 2(1):37-45.
• [15] Li Q, Chen Y, Liu Y, et al. Impact of renal function on residual platelet reactivity and clinical outcomes in patients with acute coronary syndrome treated with clopidogrel[J]. Clin Cardiol, 2021, 44(6):789-796.
• [16] Skalsky K, Shiyovich A, Steinmetz T, et al. Chronic renal failure and cardiovascular disease:a comprehensive appraisal[J]. J Clin Med, 2022, 11(5):1335.
• [17] Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes[J].Eur Heart J, 2020, 41(3):407-477.
• [18] Leszek A, Poli L, Zbinden S, et al. Outcomes with revascularization and medical therapy in patients with coronary disease and chronic kidney disease:a meta-analysis[J].Atherosclerosis, 2022, 351:41-48.
• [19] Bangalore S, Maron DJ, O’brien SM, et al. Management of coronary disease in patients with advanced kidney disease[J].N Engl J Med, 2020, 382(17):1608-1618.
• [20] Yong J, Tian J, Zhao X, et al. Optimal treatment strategies for coronary artery disease in patients with advanced kidney disease:a meta-analysis[J]. Ther Adv Chronic Dis, 2021, 12:20406223211024367.
• [21] Klein EC, Kapoor R, Lewandowski D, et al. Revascularization strategies in patients with chronic kidney disease and acute coronary syndromes[J]. Curr Cardiol Rep, 2019, 21(10):113.
• [22] Di Mauro M, Fiorentini V, Mistrulli R, et al. Acute coronary syndrome and renal impairment:a systematic review[J]. Rev Cardiovasc Med, 2022, 23(2):49.
• [23] Pavasini R, Tebaldi M, Bugani G, et al. Contrast associated acute kidney injury and mortality in older adults with acute coronary syndrome:a pooled analysis of the FRASER and HULK studies[J]. J Clin Med, 2021, 10(10):2151.
• [24] Mohebi R, Karimi Galougahi K, Garcia JJ, et al.L o n g-term clinical impact of contrast-associated acute kidney injury following PCI:an ADAPT-DES substudy[J]. JACC Cardiovasc Interv, 2022, 15(7):753-766.
• [25]中华医学会心血管病学分会介入心脏病学组，中华医学会心血管病学分会大血管病学组，中华心血管病杂志编辑委员会.经动脉心血管介入诊治中含碘对比剂相关不良反应防治的中国专家共识（2021）[J].中华心血管病杂志，2021, 49(10):972-985.
• [26] Van Der Molen AJ, Reimer P, Dekkers IA, et al. Post-contrast acute kidney injury. Part 2:risk stratifi cation, role of hydration and other prophylactic measures, patients taking metformin and chronic dialysis patients:recommendations for updated ESUR Contrast Medium Safety Committee guidelines[J]. Eur Radiol, 2018, 28(7):2856-2869.
• [27] Galougahi K, Chadban S, Mehran R, et al. Invasive management of coronary artery disease in advanced renal disease[J]. Kidney Int Rep, 2021, 6(6):1513-1524.
• [28] Nie Z, Liu Y, Wang C, et al. Safe limits of contrast media for contrast-induced nephropathy:a multicenter prospective cohort study[J]. Front Med(Lausanne), 2021, 8:701062.
• [29] Wongpraparut N, Bakoh P, Anusonadisai K, et al.Intravascular imaging guidance reduce 1-year MACE in patients undergoing rotablator atherectomy-assisted drug-eluting stent implantation[J]. Front Cardiovasc Med, 2021, 8:768313.
• [30] Kuno T, Hamaya R, Numasawa Y, et al. Outcomes With IVUS-Guided PCI[J]. JACC Cardiovasc Interv, 2020, 13(21):2579-2580.
• [31] Ogata N, Matsukage T, Toda E, et al. Intravascular ultrasound-guided percutaneous coronary interventions with minimum contrast volume for prevention of the radiocontrastinduced nephropathy:report of two cases[J]. Cardiovasc Interv Ther, 2011, 26(1):83-88.
• [32] Ali ZA, Karimi Galougahi K, Nazif T, et al. Imaging-and physiology-guided percutaneous coronary intervention without contrast administration in advanced renal failure:a feasibility,safety, and outcome study[J]. Eur Heart J, 2016, 37(40):3090-3095.
• [33] Shibata K, Wakabayashi K, Ishinaga T, et al. Feasibility,safety, and long-term outcomes of zero-contrast percutaneous coronary intervention in patients with chronic kidney disease[J].Circ J, 2022, 86(5):787-796.
• [34] Allali A, Traboulsi H, Sulimov DS, et al. Feasibility and safety of minimal-contrast IVUS-guided rotational atherectomy for complex calcified coronary artery disease[J]. Clin Res Cardiol, 2021, 110(10):1668-1679.
• [35] Chen CY, Huang W, Liu J, et al. Zero-contrast percutaneous coronary intervention for chronic total occlusions guided by intravascular ultrasound with ChromaFlo mode:a case report[J].Eur Heart J Case Rep, 2020, 4(6):1-6.
• [36] Burlacu A, Tinica G, Brinza C, et al. Safety and e ffi cacy of minimum-or zero-contrast ivus-guided percutaneous coronary interventions in chronic kidney disease patients:a systematic review[J]. J Clin Med, 2021, 10(9):1996.
• [37]李伟杰，赵志敬，孙冬冬.“零对比剂”经皮冠状动脉介入治疗1例[J].心脏杂志，2016, 28(6):747-749.
• [38]胡文瑛，严鹏勇，王睿，等.“零对比剂”经皮冠状动脉介入治疗对重度肾功能不全患者的安全性及有效性分析[J].中国介入心脏病学杂志，2021, 29(7):371-374.
• [39]张晗，窦克非，宋光远，等.血管内超声指导的零对比剂经皮冠状动脉介入治疗的安全性与有效性分析[J].中国循环杂志，2021, 36(11):1065-1069.
• [40] Cui K, Liu H, Yuan F, et al. Coronary artery bypass graft surgery versus stenting for patients with chronic kidney disease and complex coronary artery disease:a systematic review and meta-analysis[J]. Ther Adv Chronic Dis, 2021, 12:2040622321990273.